Lyvgen Biopharma Holdings Limited   Report issue

For profit Phase 1 Phase 2
Founded: Shanghai China (2016)

Organization Overview

First Clinical Trial
2019
NCT04130542
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Lyvgen Biopharma | Lyvgen Biopharma Holdings Limited

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 8